{"id":54095,"date":"2026-01-14T21:23:42","date_gmt":"2026-01-14T13:23:42","guid":{"rendered":"https:\/\/flcube.com\/?p=54095"},"modified":"2026-01-14T21:23:43","modified_gmt":"2026-01-14T13:23:43","slug":"u-yin-pharmas-eht102-gene-therapy-scores-ind-approval-under-nmpas-30-day-review-for-dfnb9-hearing-loss","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54095","title":{"rendered":"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss"},"content":{"rendered":"\n<p><strong>Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma)<\/strong> announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has approved its <strong>Investigational New Drug (IND) application for EHT102 Injection<\/strong>, a <strong>gene therapy for Autosomal Recessive Deafness 9 (DFNB9)<\/strong>, marking one of the <strong>first Class\u202f1 innovative drugs<\/strong> to successfully leverage NMPA\u2019s new <strong>30\u2011Day Review for Innovative Drug Clinical Trials<\/strong> policy enacted in September\u202f2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Shanghai U\u2011Yin Pharmaceutical (private)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>EHT102 Injection<\/td><\/tr><tr><td><strong>Application<\/strong><\/td><td>IND (Investigational New Drug)<\/td><\/tr><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Review Pathway<\/strong><\/td><td>30\u2011Day Accelerated Review for Innovative Drugs<\/td><\/tr><tr><td><strong>Approval Date<\/strong><\/td><td>12\u202fJan\u202f2026<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First gene therapy IND approved under new 30\u2011day policy<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>DFNB9 caused by biallelic OTOF gene mutations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism-of-action\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>AAV\u2011based gene therapy<\/strong> delivering functional <strong>OTOF (otoferlin) gene<\/strong> to cochlear hair cells, restoring synaptic vesicle fusion and auditory signal transmission<\/li>\n\n\n\n<li><strong>Disease Pathology:<\/strong> DFNB9 patients lack functional otoferlin protein, resulting in <strong>severe\u2011to\u2011profound congenital hearing loss<\/strong> and <strong>speech development barriers<\/strong><\/li>\n\n\n\n<li><strong>Advantages:<\/strong><\/li>\n\n\n\n<li><strong>Single\u2011administration<\/strong> intracochlear injection<\/li>\n\n\n\n<li><strong>Restores natural auditory function<\/strong> vs. artificial stimulation from cochlear implants<\/li>\n\n\n\n<li><strong>Targets root genetic cause<\/strong> rather than symptomatic treatment<\/li>\n\n\n\n<li><strong>Preclinical Data:<\/strong> In OTOF\u2011knockout mouse models, EHT102 achieved <strong>70\u201180\u202f% hearing threshold restoration<\/strong> and <strong>synaptic structure normalization<\/strong> at 6\u202fmonths post\u2011administration<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-patient-landscape\">Market Opportunity &amp; Patient Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>China<\/th><th>Global<\/th><\/tr><\/thead><tbody><tr><td><strong>Annual Births<\/strong><\/td><td>9.5\u202fmillion<\/td><td>135\u202fmillion<\/td><\/tr><tr><td><strong>DFNB9 Incidence (1:100,000)<\/strong><\/td><td>~95 newborns<\/td><td>~1,350 newborns<\/td><\/tr><tr><td><strong>Total Prevalent Cases<\/strong><\/td><td>1,200\u20111,500<\/td><td>18,000\u201122,000<\/td><\/tr><tr><td><strong>Currently Undiagnosed\/Treated<\/strong><\/td><td>70\u202f%<\/td><td>65\u202f%<\/td><\/tr><tr><td><strong>Addressable Market (2035E)<\/strong><\/td><td>450 patients<\/td><td>7,200 patients<\/td><\/tr><tr><td><strong>Average Gene Therapy Cost<\/strong><\/td><td>\u00a51.2\u202fmillion<\/td><td>$1.8\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Standard of Care:<\/strong> Hearing aids (ineffective in profound loss) and cochlear implants (provide artificial hearing, no natural sound quality)<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> <strong>No approved therapies<\/strong> restore natural hearing; families face lifetime speech therapy costs exceeding <strong>$500,000 per patient<\/strong><\/li>\n\n\n\n<li><strong>Policy Support:<\/strong> NMPA\u2019s <strong>30\u2011Day Review policy<\/strong> specifically prioritizes <strong>pediatric rare diseases<\/strong> and <strong>gene therapies<\/strong>, reflecting China\u2019s strategic push for innovation leadership<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape-amp-strategic-positioning\">Competitive Landscape &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Company<\/th><th>Drug<\/th><th>Target<\/th><th>Stage<\/th><th>Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>U\u2011Yin Pharma<\/strong><\/td><td><strong>EHT102<\/strong><\/td><td>OTOF (AAV)<\/td><td><strong>IND approved (China)<\/strong><\/td><td>First OTOF gene therapy in China<\/td><\/tr><tr><td><strong>Decibel Therapeutics<\/strong><\/td><td>DB\u2011OTO<\/td><td>OTOF (AAV)<\/td><td>Phase\u202fI\/II (US)<\/td><td>First\u2011in\u2011human; no China presence<\/td><\/tr><tr><td><strong>Akouos (Lilly)<\/strong><\/td><td>AK\u2011OTOF<\/td><td>OTOF (AAV)<\/td><td>Preclinical<\/td><td>Acquired by Lilly; US focus<\/td><\/tr><tr><td><strong>Sensorion<\/strong><\/td><td>SENS\u2011401<\/td><td>Not gene therapy<\/td><td>Phase\u202fII<\/td><td>Small molecule; symptomatic<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Speed Advantage:<\/strong> NMPA\u2019s <strong>30\u2011day review<\/strong> (vs. standard 60\u201190 days) accelerates study start by <strong>2\u20113\u202fmonths<\/strong>, enabling <strong>first patient dosed in Q1\u202f2026<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> U\u2011Yin\u2019s <strong>Shanghai gene therapy facility<\/strong> (capacity 2,000 doses\/year) GMP\u2011certified; dedicated AAV production line operational<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> Plans <strong>FDA IND filing<\/strong> in <strong>H2\u202f2026<\/strong> leveraging China data; targeting <strong>rare pediatric disease priority review voucher<\/strong> worth <strong>~$100\u202fM<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-projections\">Financial Projections<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td><strong>China DFNB9 Diagnoses<\/strong><\/td><td>85<\/td><td>95<\/td><td>105<\/td><\/tr><tr><td><strong>EHT102 Treatment Rate<\/strong><\/td><td>0\u202f%<\/td><td>55\u202f%<\/td><td>75\u202f%<\/td><\/tr><tr><td><strong>Annual Revenue (\u00a5)<\/strong><\/td><td>\u2013<\/td><td>\u00a562\u202fmillion<\/td><td>\u00a594\u202fmillion<\/td><\/tr><tr><td><strong>Operating Margin<\/strong><\/td><td>\u2013<\/td><td>68\u202f%<\/td><td>72\u202f%<\/td><\/tr><tr><td><strong>Cumulative R&amp;D Investment<\/strong><\/td><td>\u00a5180\u202fmillion<\/td><td>\u00a5240\u202fmillion<\/td><td>\u00a5300\u202fmillion<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pricing Strategy:<\/strong> Gene therapy pricing expected at <strong>\u00a51.2\u20111.5\u202fmillion<\/strong> ($170K\u2011210K), comparable to Zolgensma and Luxturna<\/li>\n\n\n\n<li><strong>Market Access:<\/strong> Eligible for <strong>China Rare Disease Insurance<\/strong> (reimbursement up to 70\u202f% in provinces like Zhejiang and Jiangsu)<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding EHT102 clinical development timelines, regulatory pathways, and commercial forecasts. Actual results may differ due to clinical trial outcomes, manufacturing scale\u2011up challenges, and competitive dynamics in the hearing loss gene therapy space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[62,66,4553],"class_list":["post-54095","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-clinical-trial-approval-initiation","tag-gene-therapy","tag-u-yin-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for EHT102 Injection, a gene therapy for Autosomal Recessive Deafness 9 (DFNB9), marking one of the first Class\u202f1 innovative drugs to successfully leverage NMPA\u2019s new 30\u2011Day Review for Innovative Drug Clinical Trials policy enacted in September\u202f2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54095\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss\" \/>\n<meta property=\"og:description\" content=\"Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for EHT102 Injection, a gene therapy for Autosomal Recessive Deafness 9 (DFNB9), marking one of the first Class\u202f1 innovative drugs to successfully leverage NMPA\u2019s new 30\u2011Day Review for Innovative Drug Clinical Trials policy enacted in September\u202f2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54095\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-14T13:23:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-14T13:23:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54095#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54095\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss\",\"datePublished\":\"2026-01-14T13:23:42+00:00\",\"dateModified\":\"2026-01-14T13:23:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54095\"},\"wordCount\":537,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"Gene therapy\",\"U\u2011Yin Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54095#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54095\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54095\",\"name\":\"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-14T13:23:42+00:00\",\"dateModified\":\"2026-01-14T13:23:43+00:00\",\"description\":\"Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for EHT102 Injection, a gene therapy for Autosomal Recessive Deafness 9 (DFNB9), marking one of the first Class\u202f1 innovative drugs to successfully leverage NMPA\u2019s new 30\u2011Day Review for Innovative Drug Clinical Trials policy enacted in September\u202f2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54095#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54095\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54095#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for EHT102 Injection, a gene therapy for Autosomal Recessive Deafness 9 (DFNB9), marking one of the first Class\u202f1 innovative drugs to successfully leverage NMPA\u2019s new 30\u2011Day Review for Innovative Drug Clinical Trials policy enacted in September\u202f2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54095","og_locale":"en_US","og_type":"article","og_title":"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss","og_description":"Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for EHT102 Injection, a gene therapy for Autosomal Recessive Deafness 9 (DFNB9), marking one of the first Class\u202f1 innovative drugs to successfully leverage NMPA\u2019s new 30\u2011Day Review for Innovative Drug Clinical Trials policy enacted in September\u202f2025.","og_url":"https:\/\/flcube.com\/?p=54095","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-14T13:23:42+00:00","article_modified_time":"2026-01-14T13:23:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54095#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54095"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss","datePublished":"2026-01-14T13:23:42+00:00","dateModified":"2026-01-14T13:23:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54095"},"wordCount":537,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Clinical trial approval \/ initiation","Gene therapy","U\u2011Yin Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54095#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54095","url":"https:\/\/flcube.com\/?p=54095","name":"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-14T13:23:42+00:00","dateModified":"2026-01-14T13:23:43+00:00","description":"Shanghai U\u2011Yin Pharmaceutical (U\u2011Yin Pharma) announced that the National Medical Products Administration (NMPA) has approved its Investigational New Drug (IND) application for EHT102 Injection, a gene therapy for Autosomal Recessive Deafness 9 (DFNB9), marking one of the first Class\u202f1 innovative drugs to successfully leverage NMPA\u2019s new 30\u2011Day Review for Innovative Drug Clinical Trials policy enacted in September\u202f2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54095#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54095"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54095#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"U\u2011Yin Pharma\u2019s EHT102 Gene Therapy Scores IND Approval Under NMPA\u2019s 30\u2011Day Review for DFNB9 Hearing Loss"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54095"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54095\/revisions"}],"predecessor-version":[{"id":54096,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54095\/revisions\/54096"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}